Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(219,585) | $(32,486) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 28 | 825 |
| Non-cash lease expense | 109 | 1,310 |
| Stock-based compensation | 8,870 | 1,933 |
| Change in fair value of warrant liabilities | 188,360 | — |
| Interest amortization on marketable securities | (488) | (11) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's D&A?
- Vor Biopharma (VOR) reported D&A of $28K in Q1 2026.
- How has Vor Biopharma's D&A changed year-over-year?
- Vor Biopharma's D&A decreased by 96.6% year-over-year, from $825K to $28K.
- What is the long-term trend for Vor Biopharma's D&A?
- Over 4 years (2021 to 2025), Vor Biopharma's D&A has grown at a 20.4% compound annual growth rate (CAGR), from $1.41M to $2.95M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Vor Biopharma's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude